US4853332A
(en)
|
1982-10-19 |
1989-08-01 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
|
FI82266C
(fi)
|
1982-10-19 |
1991-02-11 |
Cetus Corp |
Foerfarande foer framstaellning av il-2 -mutein.
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
US4530787A
(en)
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
US4572798A
(en)
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
CA1340265C
(en)
|
1985-01-18 |
1998-12-15 |
Kirston E. Koths |
Oxidation resistant muteins
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
US4816440A
(en)
|
1985-09-26 |
1989-03-28 |
Cetus Corporation |
Stable formulation of biologically active proteins for parenteral injection
|
US4863727A
(en)
|
1986-04-09 |
1989-09-05 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US5425940A
(en)
|
1986-04-09 |
1995-06-20 |
Cetus Oncology Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US5098702A
(en)
|
1986-04-09 |
1992-03-24 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US4894226A
(en)
|
1986-11-14 |
1990-01-16 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
|
WO1989004665A2
(en)
|
1987-11-25 |
1989-06-01 |
Cetus Corporation |
Treatment of infections caused by a primary immunodeficiency with interleukin-2
|
US5066489A
(en)
|
1988-03-28 |
1991-11-19 |
Cetus Corporation |
Combination therapy of IL-2 and DTIC for the treatment of melanoma
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US5153310A
(en)
|
1989-02-28 |
1992-10-06 |
Du Pont Merck Pharmaceutical Company |
Il-2 analogs containing n-linked glycosylation sites
|
NZ234674A
(en)
|
1989-08-02 |
1992-02-25 |
Seragen Inc |
Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
|
US5776427A
(en)
|
1992-03-05 |
1998-07-07 |
Board Of Regents, The University Of Texas System |
Methods for targeting the vasculature of solid tumors
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
WO1997003703A1
(en)
|
1995-07-21 |
1997-02-06 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
PT808367E
(pt)
*
|
1995-02-10 |
2007-10-22 |
Millennium Pharm Inc |
Adressinas vasculares da mucosa e suas utilizações
|
US20040115128A1
(en)
|
1995-09-08 |
2004-06-17 |
Schnitzer Jan E. |
Targeting endothelium for tissue-specific delivery of agents
|
EP1442750B1
(en)
|
1997-11-20 |
2012-08-01 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
|
JP2001523480A
(ja)
|
1997-11-20 |
2001-11-27 |
バイカル インコーポレイテッド |
サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
|
US6232287B1
(en)
|
1998-03-13 |
2001-05-15 |
The Burnham Institute |
Molecules that home to various selected organs or tissues
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
US7138103B2
(en)
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
ES2207278T3
(es)
|
1998-07-28 |
2004-05-16 |
Micromet Ag |
Heterominicuerpos.
|
US6294349B1
(en)
|
1999-03-01 |
2001-09-25 |
University Of Mississippi Medical Ctr. |
Method of diagnosing and monitoring malignant breast carcinomas
|
US6348192B1
(en)
|
1999-05-11 |
2002-02-19 |
Bayer Corporation |
Interleukin-2 mutein expressed from mammalian cells
|
US20030021792A1
(en)
|
2001-06-08 |
2003-01-30 |
Roben Paul W. |
Tissue-specific endothelial membrane proteins
|
IL149008A0
(en)
|
1999-10-04 |
2002-11-10 |
Chiron Corp |
Stabilized liquid polypeptide-containing pharmaceutical compositions
|
US20020041865A1
(en)
|
2000-01-20 |
2002-04-11 |
Richard Austin |
Methods for treating tumors
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
US6579521B2
(en)
|
2000-10-20 |
2003-06-17 |
Chiron Corporation |
Methods of therapy for HIV infection
|
US7371371B2
(en)
|
2001-08-13 |
2008-05-13 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
US20020187512A1
(en)
|
2001-09-10 |
2002-12-12 |
Nagem Ronaldo Alves Pinto |
Crystal structure of human interleukin-22
|
EP1454138B1
(en)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
ES2382800T3
(es)
|
2002-01-18 |
2012-06-13 |
Zymogenetics, Inc. |
Multímeros Zcytor17 receptores de citocinas
|
CA2498319A1
(en)
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
EP3299393A1
(en)
|
2002-11-08 |
2018-03-28 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
AU2003288675B2
(en)
|
2002-12-23 |
2010-07-22 |
Medimmune Limited |
Antibodies against PD-1 and uses therefor
|
WO2004081049A1
(en)
|
2003-03-10 |
2004-09-23 |
Auckland Uniservices Limited |
Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
CA2531773A1
(en)
|
2003-07-21 |
2005-02-17 |
Transgene S.A. |
Novel multifunctional cytokines
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
KR100632985B1
(ko)
|
2003-07-26 |
2006-10-11 |
메덱스젠 주식회사 |
생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
US8454963B2
(en)
|
2003-11-13 |
2013-06-04 |
Musc Foundation For Research Development |
Tissue targeted complement modulators
|
JP2007515185A
(ja)
|
2003-12-22 |
2007-06-14 |
カイロン コーポレイション |
免疫応答障害に対する処置ストラテジーのための診断法としてのFcレセプター多型の使用
|
SI2177537T1
(sl)
*
|
2004-01-09 |
2012-01-31 |
Pfizer |
Protitielesa proti MAdCAM
|
AU2005227263A1
(en)
|
2004-03-05 |
2005-10-06 |
Novartis Vaccines And Diagnostics, Inc. |
In vitro test system for predicting patient tolerability of therapeutic agents
|
ATE417065T1
(de)
|
2004-05-19 |
2008-12-15 |
Medigene Ltd |
Hochaffiner ny-eso-t-zellen-rezeptor
|
AU2005249540B2
(en)
|
2004-06-02 |
2009-02-19 |
Sidney Kimmel Cancer Center |
Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
|
BRPI0606774A2
(pt)
|
2005-01-27 |
2009-07-14 |
Novartis Vaccines & Diagnostic |
método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2
|
BRPI0607351A2
(pt)
|
2005-02-15 |
2009-09-01 |
Novartis Vaccines & Diagnostic |
métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20
|
AR062247A1
(es)
*
|
2005-03-08 |
2008-10-29 |
Pharmacia & Upjohn Co Llc |
Composiciones de anticuerpos anti-ctla-4
|
CN109485727A
(zh)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
PL1899364T3
(pl)
|
2005-05-17 |
2020-08-24 |
University Of Connecticut |
Kompozycje i sposoby immunomodulacji w organizmie
|
ATE483732T1
(de)
*
|
2005-07-08 |
2010-10-15 |
Pfizer Ltd |
Madcam-antikörper
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
PL1999154T3
(pl)
|
2006-03-24 |
2013-03-29 |
Merck Patent Gmbh |
Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
|
CN103351435B
(zh)
|
2006-06-06 |
2015-08-19 |
克鲁塞尔荷兰公司 |
具有杀灭葡萄球菌活性的人结合分子及其应用
|
AU2007271398B2
(en)
|
2006-07-06 |
2013-06-20 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
|
US8470323B2
(en)
|
2007-01-09 |
2013-06-25 |
The Trustees Of The University Of Pennsylvania |
Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
|
US8298545B2
(en)
|
2007-02-07 |
2012-10-30 |
The Trustees Of The University Of Pennsylvania |
Anti-autoimmune antibodies for treatment of pemphigus
|
DK2131856T3
(da)
|
2007-03-07 |
2014-12-15 |
Uti Limited Partnership |
Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
WO2009002380A2
(en)
|
2007-06-26 |
2008-12-31 |
The Trustees Of The University Of Pennsylvania |
Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
WO2009067812A1
(en)
|
2007-11-28 |
2009-06-04 |
Universite De Montreal |
Pd-1 modulation and uses thereof
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
JP5794917B2
(ja)
|
2008-09-12 |
2015-10-14 |
アイシス・イノベーション・リミテッドIsis Innovationlimited |
Pd−1特異抗体およびその使用
|
DK2344540T3
(da)
|
2008-10-02 |
2018-01-29 |
Aptevo Res & Development Llc |
Cd86-antagonist multimål bindingsproteiner
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
US20100330029A1
(en)
|
2008-10-21 |
2010-12-30 |
Merck Patent Gmbh |
Cancer Treatments with Radiation and Immunocytokines
|
MX2011007647A
(es)
|
2009-01-21 |
2011-09-01 |
Amgen Inc |
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
|
US8815297B2
(en)
|
2009-03-31 |
2014-08-26 |
Duke University |
Modulation of beta 2 adrenergic receptors by inhibitors of EGLN3 or pVHL
|
AU2010282280B2
(en)
|
2009-08-14 |
2016-06-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of IL-15 to increase thymic output and to treat lymphopenia
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
EP3112382A1
(en)
|
2009-12-29 |
2017-01-04 |
Emergent Product Development Seattle, LLC |
Heterodimer binding proteins and uses thereof
|
EP3511342B1
(en)
|
2010-03-10 |
2024-01-17 |
Genmab A/S |
Monoclonal antibodies against c-met
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
WO2011110604A1
(en)
|
2010-03-11 |
2011-09-15 |
Ucb Pharma, S.A. |
Pd-1 antibody
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
KR20230148396A
(ko)
|
2010-11-12 |
2023-10-24 |
넥타르 테라퓨틱스 |
Il-2 부분 및 중합체의 접합체
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
CA2860170C
(en)
|
2010-12-22 |
2022-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
SI2673294T1
(sl)
|
2011-02-10 |
2016-08-31 |
Roche Glycart Ag |
Mutirani polipeptidi interlevkina-2
|
WO2012112426A1
(en)
|
2011-02-14 |
2012-08-23 |
Allergan, Inc. |
Arginine vasopressin retargeted clostridial endopeptidases for use in treating benign prostatic hyperplasia
|
CA2828811C
(en)
|
2011-03-03 |
2021-09-21 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
WO2012119093A1
(en)
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
US9669071B2
(en)
|
2011-03-11 |
2017-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for stimulating T lymphocytes with IL-2
|
CN103732241A
(zh)
|
2011-03-11 |
2014-04-16 |
公共事业救济局-巴黎医院 |
低剂量il-2用于治疗自身免疫相关病症或炎性病症的应用
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
WO2012163519A1
(en)
|
2011-05-27 |
2012-12-06 |
Dutalys |
Antibodies with improved folding stability
|
JP2014525904A
(ja)
|
2011-06-28 |
2014-10-02 |
ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ |
タンパク質連結用クリックケミストリーハンドルを設置するためのソルターゼの使用
|
JP6094486B2
(ja)
|
2011-08-11 |
2017-03-15 |
小野薬品工業株式会社 |
Pd−1アゴニストからなる自己免疫疾患治療剤
|
WO2013043529A1
(en)
|
2011-09-19 |
2013-03-28 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Fc 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
US20140315817A1
(en)
|
2011-11-18 |
2014-10-23 |
Eleven Biotherapeutics, Inc. |
Variant serum albumin with improved half-life and other properties
|
KR101932697B1
(ko)
|
2012-04-27 |
2019-03-21 |
노보 노르디스크 에이/에스 |
사람 cd30 리간드 항원 결합 단백질
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
WO2013189516A1
(en)
|
2012-06-18 |
2013-12-27 |
Apeiron Biologics Ag |
Method for treating a gd2 positive cancer
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
WO2014003553A1
(en)
|
2012-06-27 |
2014-01-03 |
Arthrogen B.V. |
Combination for treating an inflammatory disorder
|
CA2878640C
(en)
|
2012-07-13 |
2023-10-24 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
AU2013301582B2
(en)
|
2012-08-07 |
2018-09-06 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
CN104968686B
(zh)
|
2012-12-05 |
2020-02-04 |
薛富盛 |
趋化素-细胞素融合蛋白和其应用
|
WO2014100014A1
(en)
|
2012-12-17 |
2014-06-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Super-2 complexes with antibody to augment il-2 therapy
|
EP2950814A4
(en)
|
2013-01-31 |
2016-06-08 |
Univ Jefferson |
PD-L1 AND PD-L2 BASED FUSION PROTEINS AND USES THEREOF
|
US20150259416A1
(en)
|
2014-03-12 |
2015-09-17 |
Biocrine Ab |
Methods for treating and/or limiting development of diabetes
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
EP2968450A4
(en)
|
2013-03-15 |
2016-10-26 |
Angelica Therapeutics Inc |
MODIFIED TOXINS
|
US10150800B2
(en)
|
2013-03-15 |
2018-12-11 |
Zyngenia, Inc. |
EGFR-binding modular recognition domains
|
JP6603209B2
(ja)
|
2013-05-10 |
2019-11-06 |
ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ |
ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾
|
EP3029065B1
(en)
|
2013-06-06 |
2020-05-27 |
Hefei Lifeon Pharmaceutical Co. Ltd. |
Human antibody against ed-b domain of fibronectin and uses thereof
|
US10519247B2
(en)
|
2013-11-01 |
2019-12-31 |
Board Of Regents,The University Of Texas System |
Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
JP6306201B2
(ja)
|
2014-02-06 |
2018-04-04 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
インターロイキン−2融合タンパク質及びその使用
|
EP3105333B1
(en)
|
2014-02-10 |
2020-04-08 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
EP2918285A1
(en)
|
2014-03-11 |
2015-09-16 |
Université Pierre et Marie Curie (Paris 6) |
Interleukin-2 for treating food allergy
|
ES2864124T3
(es)
|
2014-03-11 |
2021-10-13 |
Molecular Templates Inc |
Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
|
EP3134102B1
(en)
|
2014-04-24 |
2019-07-03 |
The Board of Trustees of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
ES2717751T3
(es)
|
2014-06-11 |
2019-06-25 |
Molecular Templates Inc |
Polipéptidos efectores de la subunidad A de la toxina de Shiga resistentes a la escisión por proteasa y moléculas dirigidas a células que los comprenden
|
EP2963057A1
(en)
|
2014-07-02 |
2016-01-06 |
Calypso Biotech SA |
Antibodies to IL-15
|
ES2763198T3
(es)
|
2014-07-21 |
2020-05-27 |
Delinia Inc |
Moléculas que selectivamente activan las células T reguladoras para el tratamiento de enfermedades autoinmunes
|
AU2015294834B2
(en)
|
2014-07-31 |
2021-04-29 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
CN107074947B
(zh)
|
2014-08-05 |
2021-04-09 |
马布奎斯特公司 |
结合至pd-1的免疫试剂
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
NZ728175A
(en)
|
2014-08-11 |
2023-03-31 |
Delinia Inc |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
DK3180018T3
(da)
|
2014-08-12 |
2019-10-28 |
Massachusetts Inst Technology |
Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
|
CA2951604A1
(en)
|
2014-08-29 |
2016-03-03 |
Pablo Umana |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
DK3209685T3
(da)
|
2014-10-23 |
2019-07-29 |
Singh Molecular Medicine Llc |
Enkeltdomæneantistoffer rettet mod intracellulære antigener
|
DK3233192T3
(da)
|
2014-12-15 |
2021-07-19 |
Univ Washington |
Sammensætninger og fremgangsmåder til målrettet cytokinindgivelse
|
US20160206666A1
(en)
|
2014-12-22 |
2016-07-21 |
Synlogic, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
|
EP3916017A1
(en)
|
2014-12-22 |
2021-12-01 |
PD-1 Acquisition Group, LLC |
Anti-pd-1 antibodies
|
US20170369871A1
(en)
|
2015-01-12 |
2017-12-28 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
MX2017011644A
(es)
|
2015-03-13 |
2017-12-04 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
|
EP3280443B1
(en)
|
2015-04-08 |
2022-08-24 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind cd38
|
WO2016164937A2
(en)
|
2015-04-10 |
2016-10-13 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
DK3326641T3
(da)
|
2015-04-22 |
2019-09-30 |
Curevac Ag |
Rna-holdig sammensætning til behandling af tumorsygdomme
|
AU2016256876B2
(en)
|
2015-05-05 |
2021-02-04 |
Rubicon Biotechnology Llc |
Cancer immunotherapeutic
|
GB201507908D0
(en)
|
2015-05-08 |
2015-06-24 |
Philogen Spa |
IL2 and TNF immunoconjugates
|
CN114425077A
(zh)
|
2015-05-18 |
2022-05-03 |
起源生物医药公司 |
Sirp多肽组合物和使用方法
|
EP3307876B1
(en)
|
2015-06-10 |
2023-09-13 |
ImmunityBio, Inc. |
Modified nk-92 cells for treating cancer
|
CN108337890B
(zh)
|
2015-06-23 |
2021-10-15 |
纪念斯隆-凯特琳癌症中心 |
新型pd-1免疫调节剂
|
JP7370691B2
(ja)
|
2015-06-30 |
2023-10-30 |
ナノティックス,エルエルシー |
スカベンジャー粒子に関連する組成物及び方法
|
US10653790B2
(en)
|
2015-07-29 |
2020-05-19 |
Nanotics, Llc |
Compositions and methods related to scavenger particles
|
WO2017023780A1
(en)
|
2015-07-31 |
2017-02-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates for targeting cd56-positive tumors
|
WO2017036255A1
(en)
|
2015-09-01 |
2017-03-09 |
Tse-Wen Chang |
Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
|
WO2017044464A1
(en)
|
2015-09-11 |
2017-03-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Biologically relevant orthogonal cytokine/receptor pairs
|
AR106184A1
(es)
|
2015-09-29 |
2017-12-20 |
Celgene Corp |
Proteínas de unión a pd-1 y sus métodos de uso
|
AU2016332900C1
(en)
|
2015-09-29 |
2024-02-01 |
Amgen Inc. |
ASGR inhibitors
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
US10722460B2
(en)
|
2015-10-22 |
2020-07-28 |
Iltoo Pharma |
Pharmaceutical compositions of IL-2
|
US10138298B2
(en)
|
2015-10-23 |
2018-11-27 |
The Regents Of The University Of California |
Anti-IL-2 antibodies and compositions and uses thereof
|
TW201726149A
(zh)
|
2015-10-23 |
2017-08-01 |
理查 P 榮漢斯 |
用於免疫療法之組合方法
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
ES2873846T3
(es)
|
2015-11-19 |
2021-11-04 |
Revitope Ltd |
Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas
|
EP3978010A1
(en)
|
2015-12-02 |
2022-04-06 |
Fred Hutchinson Cancer Research Center |
Circular tandem repeat proteins
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
BR112018003984A2
(pt)
|
2015-12-09 |
2018-09-25 |
Hoffmann La Roche |
anticorpos
|
WO2017102010A1
(en)
|
2015-12-17 |
2017-06-22 |
Biontech Rna Pharmaceuticals Gmbh |
Novel cytokine fusion proteins
|
US20190002516A1
(en)
|
2015-12-21 |
2019-01-03 |
Hefei Lifeon Pharmaceutical Co., Ltd. |
Drug Design Method, Obtained Drug and Application Thereof
|
US20190016796A1
(en)
|
2016-01-11 |
2019-01-17 |
Universitat Zurich |
Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
|
WO2017123675A1
(en)
|
2016-01-11 |
2017-07-20 |
Synlogic, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
KR20180100224A
(ko)
|
2016-01-11 |
2018-09-07 |
노바르티스 아게 |
인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질
|
JP7292877B2
(ja)
|
2016-01-14 |
2023-06-19 |
イントレクソン・アクトバイオテイクス・エヌブイ |
1型糖尿病を処置するための組成物および方法
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
US11053293B2
(en)
|
2016-02-05 |
2021-07-06 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
CN117024599A
(zh)
|
2016-02-05 |
2023-11-10 |
奥里尼斯生物科学私人有限公司 |
双特异性信号传导剂及其用途
|
WO2017139570A1
(en)
|
2016-02-12 |
2017-08-17 |
Massachusetts Intitute Of Technology |
Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
|
ES2718192T3
(es)
|
2016-02-25 |
2019-06-28 |
Provecs Medical Gmbh |
Sistema vector inmunoestimulante novedoso
|
EP3426278B1
(en)
|
2016-03-07 |
2024-01-03 |
Vib Vzw |
Cd20 binding single domain antibodies
|
CN109790545A
(zh)
|
2016-03-10 |
2019-05-21 |
约翰·霍普金斯大学 |
产生不含聚集物的单体白喉毒素融合蛋白的方法和治疗用途
|
JP6911044B2
(ja)
|
2016-03-16 |
2021-07-28 |
シェ、ヤンホイXie Yanhui |
呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン2の組合せ
|
US11186641B2
(en)
|
2016-03-17 |
2021-11-30 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
AU2017249694B2
(en)
|
2016-04-12 |
2019-10-03 |
Philogen S.P.A. |
Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (CAR)-T cell
|
ES2864095T3
(es)
|
2016-04-15 |
2021-10-13 |
Philogen Spa |
Anticuerpo anti-tenascina no glicosilado
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
EP3453401A4
(en)
|
2016-05-06 |
2020-01-29 |
Wang, Mulin |
INTERLEUKIN COMBINATION AND THEIR USE
|
GB201608192D0
(en)
|
2016-05-10 |
2016-06-22 |
Immunovia Ab |
Method, array and use thereof
|
EP3458485B1
(en)
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
AU2017269764A1
(en)
|
2016-05-25 |
2018-12-13 |
F. Hoffmann-La Roche Ag |
Materials and methods relating to dosage regimen design
|
EP3463440A4
(en)
|
2016-05-27 |
2020-04-15 |
Etubics Corporation |
NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF
|
CA3026342A1
(en)
|
2016-06-03 |
2017-12-07 |
Etubics Corporation |
Compositions and methods for tumor vaccination using prostate cancer-associated antigens
|
JP2019517522A
(ja)
|
2016-06-03 |
2019-06-24 |
エトゥビクス コーポレーション |
ヒトパピローマウイルス(hpv)関連疾患の処置のための組成物及び方法
|
CA3026345A1
(en)
|
2016-06-03 |
2017-12-07 |
Etubics Corporation |
Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
CA3028829A1
(en)
|
2016-06-22 |
2017-12-28 |
David Klatzmann |
Genetically modified t lymphocytes
|
US11141463B2
(en)
|
2016-07-11 |
2021-10-12 |
The National Institute for Biotechnology in the Negev Ltd. |
Fusion proteins with extended serum half life
|
AU2017297608B2
(en)
|
2016-07-15 |
2020-03-19 |
Etubics Corporation |
Compositions and methods for flavivirus vaccination
|
CA3030451C
(en)
|
2016-07-15 |
2023-09-05 |
Etubics Corporation |
Compositions and methods for alphavirus vaccination
|
GB201614093D0
(en)
|
2016-08-17 |
2016-09-28 |
Autolus Ltd |
Vector
|
JP2019528284A
(ja)
|
2016-08-17 |
2019-10-10 |
ファクター バイオサイエンス インコーポレイテッド |
核酸産物およびその投与方法
|
US20200330557A1
(en)
|
2016-08-19 |
2020-10-22 |
Brooklyn Immunotherapeutics Llc |
Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
|
JP2020501508A
(ja)
|
2016-09-15 |
2020-01-23 |
クアドルセプト バイオ リミテッド |
多量体、四量体および八量体
|
EP3515944A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
AU2017331277B2
(en)
|
2016-09-23 |
2024-05-30 |
Marengo Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
AU2017336094A1
(en)
|
2016-09-29 |
2019-04-18 |
Immunitybio, Inc. |
HLA class I-deficient NK-92 cells with decreased immunogenicity
|
AU2017359172A1
(en)
|
2016-11-08 |
2019-05-16 |
Delinia, Inc. |
IL-2 variants for the treatment of autoimmune diseases
|
EP3538130A4
(en)
|
2016-11-10 |
2020-06-03 |
Nektar Therapeutics |
IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE
|
US10011269B2
(en)
|
2016-11-30 |
2018-07-03 |
Ford Global Technologies, Llc |
Identifying in-range fuel pressure sensor error
|
CA3044416A1
(en)
|
2016-12-13 |
2018-06-21 |
Delinia, Inc. |
Multivalent regulatory t cell modulators
|
US20190352361A1
(en)
|
2016-12-15 |
2019-11-21 |
The Brigham And Women`S Hospital, Inc. |
Tissue-based biologics for the treatment of inflammatory and autoimmune disorders
|
DK3558339T3
(da)
|
2016-12-22 |
2024-02-26 |
Cue Biopharma Inc |
T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
|
US10232053B2
(en)
|
2016-12-30 |
2019-03-19 |
Trieza Therapeutics, Inc. |
Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
|
JP2020504177A
(ja)
|
2017-01-04 |
2020-02-06 |
ナノティックス,エルエルシー |
捕捉粒子をアセンブルするための方法
|
WO2018129188A1
(en)
|
2017-01-04 |
2018-07-12 |
Nanotics, Llc |
Methods for assembling scavenging particles
|
WO2018129346A1
(en)
|
2017-01-06 |
2018-07-12 |
Nantkwest, Inc. |
Genetically modified nk-92 cells with decreased cd96/tigit expression
|
US20200121719A1
(en)
|
2017-01-06 |
2020-04-23 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
AU2018207303A1
(en)
|
2017-01-10 |
2019-07-25 |
xCella Biosciences, Inc. |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
|
US20200000862A1
(en)
|
2017-02-03 |
2020-01-02 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Oncolytic virus therapy
|
WO2018151868A2
(en)
|
2017-02-16 |
2018-08-23 |
Sonnet Bio Therapeutics |
Albumin binding domain fusion proteins
|
EP3589303A4
(en)
|
2017-03-01 |
2020-11-25 |
Nektar Therapeutics |
IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE USING AN INTERLEUKIN-2 RECEPTOR ALPHA, BETA-SELECTIVE AGONIST IN COMBINATION WITH ADOPTIVE CELL TRANSFER THERAPY
|
EP3596108A4
(en)
|
2017-03-15 |
2020-12-23 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
US20200010528A1
(en)
|
2017-03-15 |
2020-01-09 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
PT3606946T
(pt)
|
2017-04-03 |
2022-10-17 |
Hoffmann La Roche |
Imunoconjugados de um anticorpo anti-pd-1 com uma il-2 mutante ou com il-15
|
CN108686202A
(zh)
|
2017-04-06 |
2018-10-23 |
张晋宇 |
肿瘤免疫疗法
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
CA3058279A1
(en)
|
2017-04-13 |
2018-10-18 |
F.Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
|
MX2019013202A
(es)
|
2017-05-10 |
2020-01-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos de infiltracion de tumor a partir de tumores liquidos y usos terapeuticos de los mismos.
|
EP3634980B1
(en)
|
2017-05-15 |
2023-07-19 |
University of Miami |
Materials and methods for subjects at risk for viral reactivation
|
WO2019112852A1
(en)
|
2017-12-06 |
2019-06-13 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
AU2018274216A1
(en)
|
2017-05-24 |
2019-12-12 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
WO2018215938A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
JP2020521452A
(ja)
|
2017-05-24 |
2020-07-27 |
パンディオン・セラピューティクス・インコーポレイテッド |
標的化免疫寛容
|
US20210277085A1
(en)
|
2017-05-24 |
2021-09-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
US11819517B2
(en)
|
2017-06-05 |
2023-11-21 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
EP3634485A4
(en)
|
2017-06-07 |
2021-07-21 |
Silverback Therapeutics, Inc. |
CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
|
MX2019014960A
(es)
|
2017-06-12 |
2020-08-06 |
Obsidian Therapeutics Inc |
Composiciones de fosfodiesterasa de tipo 5 (pde5) y métodos de inmunoterapia.
|
US11845806B2
(en)
|
2017-06-14 |
2023-12-19 |
Dingfu Biotarget Co., Ltd. |
Proteinaceous heterodimer and use thereof
|
EP3641814A4
(en)
|
2017-06-19 |
2021-06-23 |
Medicenna Therapeutics Inc. |
USES AND METHODS FOR IL-2 SUPERAGONISTS, AGONISTS, AND FUSIONS THEREOF
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
AU2018298063A1
(en)
|
2017-07-03 |
2020-02-20 |
Torque Therapeutics, Inc. |
Polynucleotides encoding immunostimulatory fusion molecules and uses thereof
|
US20200149053A1
(en)
|
2017-07-12 |
2020-05-14 |
Synlogic Operating Company, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
US20190023760A1
(en)
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
WO2019028425A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
CONJUGATES OF CYTOKINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
JP7290013B2
(ja)
|
2017-08-04 |
2023-06-13 |
ジェンマブ エー/エス |
Pd-l1およびcd137に結合する結合物質ならびにその使用
|
JP7347899B2
(ja)
|
2017-08-09 |
2023-09-20 |
オリオンズ バイオサイエンス インコーポレイテッド |
Cd8結合物質
|
JP7423511B2
(ja)
|
2017-08-09 |
2024-01-29 |
オリオンズ バイオサイエンス インコーポレイテッド |
Pd-1およびpd-l1結合物質
|
MX2020001513A
(es)
|
2017-08-09 |
2020-08-20 |
Orionis Biosciences Inc |
Agentes de union a clec9a y su uso.
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
CN111328288A
(zh)
|
2017-08-18 |
2020-06-23 |
磨石肿瘤生物技术公司 |
靶向共同抗原的抗原结合蛋白
|
WO2019046815A1
(en)
|
2017-08-31 |
2019-03-07 |
Poseida Therapeutics, Inc. |
TRANSPOSON SYSTEM AND METHODS OF USE
|
WO2019051127A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
|
TW201920248A
(zh)
|
2017-09-07 |
2019-06-01 |
美商信號生物製藥公司 |
多聚體t細胞調節多肽及其使用方法
|
CN111278864A
(zh)
|
2017-09-07 |
2020-06-12 |
库尔生物制药有限公司 |
抗原呈递多肽及其使用方法
|
TW201925235A
(zh)
|
2017-09-07 |
2019-07-01 |
美商信號生物製藥公司 |
具有化學結合位點之抗原呈現多肽及其使用方法
|
AU2018329741A1
(en)
|
2017-09-08 |
2020-03-19 |
Poseida Therapeutics, Inc. |
Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
|
US20200263196A1
(en)
|
2017-09-27 |
2020-08-20 |
Sigilon Therapeutics, Inc. |
Methods, compositions, and implantable elements comprising active cells
|
US11192943B2
(en)
|
2017-09-30 |
2021-12-07 |
Hefei Lifeon Pharmaceutical Co., Ltd. |
Protein binding to fibronectin B domain
|
US11474271B2
(en)
|
2017-10-24 |
2022-10-18 |
Schlumberger Technology Corporation |
Methods and systems for automated sonic imaging
|
WO2019084284A1
(en)
|
2017-10-27 |
2019-05-02 |
Coneksis, Inc. |
NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
|
WO2019091384A1
(en)
|
2017-11-08 |
2019-05-16 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
Conjugates of biomolecule and use thereof
|
JP2021502422A
(ja)
|
2017-11-13 |
2021-01-28 |
エクストレモチェム・エルディーエー.Extremochem,Lda. |
生体分子の安定剤としての中性のグリコシル化されたアミド及びジアニオン性のグルクロン酸化された酸
|
CN111601883A
(zh)
|
2017-11-17 |
2020-08-28 |
艾欧凡斯生物治疗公司 |
由细针抽吸物和小活检物扩增til
|
MX2020005041A
(es)
|
2017-11-21 |
2020-10-12 |
Univ Leland Stanford Junior |
Agonistas parciales de interleucina-2.
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
CA3084262A1
(en)
|
2017-12-06 |
2019-06-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Engineered proteins to enhance sensitivity of a cell to il-2
|
AU2018378078A1
(en)
|
2017-12-06 |
2020-06-18 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
CN111479917A
(zh)
|
2017-12-13 |
2020-07-31 |
詹森生物科技公司 |
经基因修饰以消除T细胞受体和β2-微球蛋白表达的永生化CAR-T细胞
|
CA3085765A1
(en)
|
2017-12-15 |
2019-06-20 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
WO2019122882A1
(en)
|
2017-12-19 |
2019-06-27 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
EP3502139A1
(en)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antibodies to tumour antigens
|
WO2019125732A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
US20210139557A1
(en)
|
2017-12-20 |
2021-05-13 |
Poseida Therapeutics, Inc. |
Vcar compositions and methods for use
|
JP7336457B2
(ja)
|
2017-12-26 |
2023-08-31 |
ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド |
抗体Fc領域を主鎖として用いた融合タンパク質二量体及びその使用
|
CA3086842A1
(en)
|
2017-12-27 |
2019-07-04 |
Kyowa Kirin Co., Ltd. |
Il-2 variant
|
US20210079106A1
(en)
|
2017-12-28 |
2021-03-18 |
Julius-Maximilians-Universität Würzburg |
TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
|
BR112020013848A2
(pt)
|
2018-01-08 |
2020-12-01 |
Iovance Biotherapeutics, Inc. |
métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
EP3737689A4
(en)
|
2018-01-09 |
2021-12-01 |
Cue Biopharma, Inc. |
MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
|
WO2019144309A1
(en)
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
WO2019147837A2
(en)
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine fusion proteins
|
TWI708787B
(zh)
|
2018-03-02 |
2020-11-01 |
美商美國禮來大藥廠 |
Pd-1促效劑抗體及其用途
|
AU2019230192A1
(en)
|
2018-03-07 |
2020-10-08 |
Poseida Therapeutics, Inc. |
CARTyrin compositions and methods for use
|
CA3115461A1
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
JP2021530223A
(ja)
|
2018-07-09 |
2021-11-11 |
スロゼン, インコーポレイテッド |
組織特異性Wntシグナル増強分子及びその使用
|
EP3827014A1
(en)
|
2018-07-24 |
2021-06-02 |
BioNTech RNA Pharmaceuticals GmbH |
Il2 agonists
|
JP2022501433A
(ja)
|
2018-09-18 |
2022-01-06 |
パンディオン・オペレーションズ・インコーポレイテッド |
標的化された免疫寛容
|
WO2020163646A1
(en)
|
2019-02-08 |
2020-08-13 |
Igm Biosciences, Inc. |
Anti-gitr antigen-binding domains and uses thereof
|
JP2022533702A
(ja)
|
2019-05-20 |
2022-07-25 |
パンディオン・オペレーションズ・インコーポレイテッド |
MAdCAM標的化免疫寛容
|
AU2020333757A1
(en)
*
|
2019-08-19 |
2022-03-24 |
Pandion Operations, Inc. |
Targeted immunotolerance with a PD-1 agonist
|
US11095944B2
(en)
|
2019-08-19 |
2021-08-17 |
Roku, Inc. |
Content-modification system with broadcast schedule utilization feature
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
WO2021168192A2
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
|
CN116368155A
(zh)
|
2020-08-19 |
2023-06-30 |
潘迪恩运营公司 |
多互补位抗pd-1抗体及其用途
|
WO2022082019A2
(en)
|
2020-10-16 |
2022-04-21 |
Pandion Operations, Inc. |
Kidney targeted immunotolerance
|
WO2022082014A2
(en)
|
2020-10-16 |
2022-04-21 |
Pandion Operations, Inc. |
Skin targeted immunotolerance
|